These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 14631268)

  • 1. [Oestro-progestagen treatment combined with rivastigmine in menopausal women suffering from Alzheimer's disease. The results of a 28-weeks controlled study].
    Rigaud AS; André G; Vellas B; Touchon J; Pere JJ; Loria-Kanza Y
    Presse Med; 2003 Oct; 32(35):1649-54. PubMed ID: 14631268
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
    Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
    Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
    Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
    Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term effects of rivastigmine treatment on neuropsychiatric and behavioral disturbances in nursing home residents with moderate to severe Alzheimer's disease: results of a 52-week open-label study.
    Aupperle PM; Koumaras B; Chen M; Rabinowicz A; Mirski D
    Curr Med Res Opin; 2004 Oct; 20(10):1605-12. PubMed ID: 15462693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
    Kumar V; Anand R; Messina J; Hartman R; Veach J
    Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial.
    Rösler M; Anand R; Cicin-Sain A; Gauthier S; Agid Y; Dal-Bianco P; Stähelin HB; Hartman R; Gharabawi M
    BMJ; 1999 Mar; 318(7184):633-8. PubMed ID: 10066203
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
    Forette F; Anand R; Gharabawi G
    Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of rivastigmine in subjects with moderately severe Alzheimer's disease.
    Burns A; Spiegel R; Quarg P
    Int J Geriatr Psychiatry; 2004 Mar; 19(3):243-9. PubMed ID: 15027039
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Presentation and stability of cognitive and noncognitive symptom patterns in patients with Alzheimer's disease. Disease course over a two-year period under constant treatment conditions with rivastigmine].
    Wobrock T; Retz-Junginger P; Retz W; Supprian T; Rösler M
    Fortschr Neurol Psychiatr; 2003 Apr; 71(4):199-204. PubMed ID: 12677553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
    D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
    Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An open-label study to evaluate the safety, tolerability and efficacy of rivastigmine in patients with mild to moderate probable Alzheimer's disease in the community setting.
    Bilikiewicz A; Opala G; Podemski R; Puzyński S; Łapin J; Sołtys K; Ochudło S; Barcikowska M; Pfeffer A; Bilińska M; Paradowski B; Parnowski T; Gabryelewicz T
    Med Sci Monit; 2002 Feb; 8(2):PI9-15. PubMed ID: 11859291
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potential long-term effects of rivastigmine on disease progression may be linked to drug effects on vascular changes in Alzheimer brains.
    Erkinjuntti T; Skoog I; Lane R; Andrews C
    Int J Clin Pract; 2003 Nov; 57(9):756-60. PubMed ID: 14686563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
    Mets T; Vandewoude M; Jacquy J; Deblander A; MacDonald K; Sloesen A; Abraham I;
    Curr Med Res Opin; 2007 Oct; 23(10):2485-501. PubMed ID: 17784995
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 12-month study of the efficacy of rivastigmine in patients with advanced moderate Alzheimer's disease.
    Karaman Y; Erdoğan F; Köseoğlu E; Turan T; Ersoy AO
    Dement Geriatr Cogn Disord; 2005; 19(1):51-6. PubMed ID: 15383747
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of higher-dose 13.3 mg/24 h (15 cm2) rivastigmine patch on the Alzheimer's Disease Assessment Scale-cognitive subscale: domain and individual item analysis.
    Alva G; Isaacson R; Sadowsky C; Grossberg G; Meng X; Somogyi M
    Int J Geriatr Psychiatry; 2014 Sep; 29(9):920-7. PubMed ID: 24549933
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of age on response to rivastigmine or donepezil in patients with Alzheimer's disease.
    Bullock R; Bergman H; Touchon J; Gambina G; He Y; Nagel J; Lane R
    Curr Med Res Opin; 2006 Mar; 22(3):483-94. PubMed ID: 16574032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term effects of rivastigmine in moderately severe Alzheimer's disease: does early initiation of therapy offer sustained benefits?
    Doraiswamy PM; Krishnan KR; Anand R; Sohn H; Danyluk J; Hartman RD; Veach J
    Prog Neuropsychopharmacol Biol Psychiatry; 2002 May; 26(4):705-12. PubMed ID: 12188103
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response of patients with Alzheimer disease to rivastigmine treatment is predicted by the rate of disease progression.
    Farlow MR; Hake A; Messina J; Hartman R; Veach J; Anand R
    Arch Neurol; 2001 Mar; 58(3):417-22. PubMed ID: 11255445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rivastigmine. A review of its use in Alzheimer's disease.
    Spencer CM; Noble S
    Drugs Aging; 1998 Nov; 13(5):391-411. PubMed ID: 9829166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.